Scancell Holdings plc (‘Scancell’ or the ‘Company’), the developer of novel immunotherapies for the treatment of cancer, will host its Annual General Meeting on Tuesday 14 October 2014.
AGM details are as follows:
||Tuesday 14 October 2014
||Thistle Hotel EMA
East Midlands Airport
The AGM presentation will include an update on the progress of the SCIB1 clinical programme and will also highlight progress on the development of both the ImmunoBody® and Moditope® platforms.
For Further Information:
Dr Richard Goodfellow, Joint CEO
|Scancell Holdings Plc
||+ 44 (0) 20 3727 1000
|Professor Lindy Durrant, Joint CEO
||Scancell Holdings Plc
Christopher Golden/Stephen Keys
+44 (0) 20 77397 8900
|Mo Noonan/Simon Conway
+ 44 (0) 20 3727 1000
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.
Pre-clinical data on a combination of SCIB1 and checkpoint inhibition (blockade of the PD-1 immune checkpoint pathway), has shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.